Ryota Kondou

512 total citations
18 papers, 358 citations indexed

About

Ryota Kondou is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Ryota Kondou has authored 18 papers receiving a total of 358 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 13 papers in Immunology and 4 papers in Molecular Biology. Recurrent topics in Ryota Kondou's work include Cancer Immunotherapy and Biomarkers (14 papers), Immunotherapy and Immune Responses (9 papers) and CAR-T cell therapy research (7 papers). Ryota Kondou is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Immunotherapy and Immune Responses (9 papers) and CAR-T cell therapy research (7 papers). Ryota Kondou collaborates with scholars based in Japan and Nigeria. Ryota Kondou's co-authors include Yasuto Akiyama, Tadashi Ashizawa, Akira Iizuka, Takashi Sugino, Ken Yamaguchi, Haruo Miyata, Koichi Mitsuya, Nakamasa Hayashi, Yoko Nakasu and Mamoru Ito and has published in prestigious journals such as Clinical Cancer Research, International Journal of Oncology and Immunology Letters.

In The Last Decade

Ryota Kondou

18 papers receiving 350 citations

Peers

Ryota Kondou

ONCOL

IMMUN

GENET

Mariano F. Zacarías Fluck Spain

Valentin Bruttel Germany

Claire Banissi France

Tania Rodríguez-Cruz United States

Karine Flem‐Karlsen Norway

Justin Wang United States

Betelehem W. Yacob United States

Nicholas Papadopoulos United States

Anastasia S. Proskurina Russia

Е. В. Долгова Russia

Mariano F. Zacarías Fluck Spain

Ryota Kondou

236 ×1.0

ONCOL

186 ×1.0

IMMUN

176 ×1.7

22 ×0.4

GENET

87 ×2.3

Citations per year, relative to Ryota Kondou Ryota Kondou (= 1×) peers Mariano F. Zacarías Fluck

Countries citing papers authored by Ryota Kondou

Since Specialization

Citations

This map shows the geographic impact of Ryota Kondou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryota Kondou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryota Kondou more than expected).

Fields of papers citing papers by Ryota Kondou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryota Kondou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryota Kondou. The network helps show where Ryota Kondou may publish in the future.

Co-authorship network of co-authors of Ryota Kondou

This figure shows the co-authorship network connecting the top 25 collaborators of Ryota Kondou. A scholar is included among the top collaborators of Ryota Kondou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryota Kondou. Ryota Kondou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Akiyama, Yasuto, Tadashi Ashizawa, Akira Iizuka, et al.. (2022). Development of Novel Small Antitumor Compounds Inhibiting PD-1/PD-L1 Binding. Anticancer Research. 42(11). 5233–5247. 4 indexed citations

Miyata, Haruo, Yasuto Akiyama, Akira Iizuka, et al.. (2021). Development of an Automatic Measurement Method for CD8 and PD-1 Positive T Cells Using Image Analysis Software. Anticancer Research. 42(1). 419–427. 3 indexed citations

Iizuka, Akira, Haruo Miyata, Ryota Kondou, et al.. (2021). Alternative Evaluation of an ELISPOT Assay Using Cytokine Activity as a Novel Parameter. Anticancer Research. 41(8). 3825–3831. 3 indexed citations

Mitsuya, Koichi, Yasuto Akiyama, Akira Iizuka, et al.. (2020). Alpha-type-1 Polarized Dendritic Cell-based Vaccination in Newly Diagnosed High-grade Glioma: A Phase II Clinical Trial. Anticancer Research. 40(11). 6473–6484. 30 indexed citations

Iizuka, Akira, Tadashi Ashizawa, Ryota Kondou, et al.. (2019). A T-cell–engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer. Clinical Cancer Research. 25(9). 2925–2934. 61 indexed citations

Ashizawa, Tadashi, Akira Iizuka, Emiko Tanaka, et al.. (2019). Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status. Immunology Letters. 216. 43–50. 24 indexed citations

Otsuka, Masaki, Ryota Kondou, Akira Iizuka, et al.. (2019). Identification of a neoantigen epitope in a melanoma patient with good response to anti-PD-1 antibody therapy. Immunology Letters. 208. 52–59. 8 indexed citations

Ashizawa, Tadashi, Akira Iizuka, Emiko Tanaka, et al.. (2019). Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse. Biomedical Research. 40(6). 243–250. 34 indexed citations

Kondou, Ryota, Akira Iizuka, Haruo Miyata, et al.. (2018). Classification of tumor microenvironment immune types based on immune response-associated gene expression. International Journal of Oncology. 54(1). 219–228. 12 indexed citations

10.

Kiyohara, Yoshio, Shusuke Yoshikawa, Masaki Otsuka, et al.. (2017). Melanoma patient response to nivolumab treatment for metastatic lung lesions: Multi‐OMICS analysis in Project HOPE. The Journal of Dermatology. 44(10). 1156–1159. 1 indexed citations

11.

Akiyama, Yasuto, Tadashi Ashizawa, Akira Iizuka, et al.. (2017). The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line. Immunology Letters. 190. 20–25. 28 indexed citations

12.

Miyata, Haruo, Tadashi Ashizawa, Akira Iizuka, et al.. (2017). Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line. Cancer Genomics & Proteomics. 14(1). 83–92. 34 indexed citations

13.

Yoshikawa, Shusuke, Yoshio Kiyohara, Masaki Otsuka, et al.. (2017). Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE. Anticancer Research. 37(3). 1321–1328. 6 indexed citations

14.

Akiyama, Yasuto, Yoshio Kiyohara, Shusuke Yoshikawa, et al.. (2017). Immune response-associated gene profiling in Japanese melanoma patients using multi-omics analysis. Oncology Reports. 39(3). 1125–1131. 2 indexed citations

15.

Ashizawa, Tadashi, Akira Iizuka, Ryota Kondou, et al.. (2016). Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse. Clinical Cancer Research. 23(1). 149–158. 77 indexed citations

16.

Akiyama, Yasuto, Ryota Kondou, Haruo Miyata, et al.. (2016). Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells. International Journal of Oncology. 49(3). 1099–1107. 18 indexed citations

17.

Iizuka, Akira, Ryota Kondou, Tadashi Ashizawa, et al.. (2016). Unstable B7-H4 cell surface expression and T-cell redirection as a means of cancer therapy. Oncology Reports. 36(5). 2625–2632. 5 indexed citations

18.

Akiyama, Yasuto, Ryota Kondou, Akira Iizuka, et al.. (2016). <b>Immune response-associated gene analysis of 1,000 cancer patients using whole-exome sequencing and gene expression profiling—Project </b><b>HOPE— </b>. Biomedical Research. 37(4). 233–242. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact